Agorà for Scientific Research: a shared commitment with Fondazione Umberto Veronesi in support of oncological research

Scientific research represents one of the fundamental pillars for the advancement of medicine and for the tangible improvement of prevention, diagnosis, and treatment of oncological diseases.

Within this framework lies the long-standing commitment of Agorà for Scientific Research, which since 2020 has been funding an annual research fellowship in collaboration with Fondazione Umberto Veronesi ETS.

Bearing witness to the value of this shared path, Professor Paolo Veronesi expressed his appreciation through an institutional video message, highlighting the importance of contributions from scientific societies such as Agorà in promoting rigorous, independent oncological research aimed at advancing clinical practice.

The mission of Agorà: prevention, information, and comprehensive patient care

Agorà’s mission is to ensure a comprehensive, 360-degree approach to patient care, placing prevention at the core as an essential tool for identifying disease at its earliest stages. In parallel, Agorà promotes accurate scientific information, which is crucial to supporting patients throughout their entire care pathway and to ensuring the best possible quality of life. As a Scientific Society, this commitment is also reflected in tangible support for oncological research through the funding of dedicated research fellowships.

Supported research projects

Over the years, the research fellowships supported by Agorà have addressed areas of major scientific and clinical relevance. Complementing these projects are short video recaps in which the fellowship recipients present the objectives, methodologies, and potential impact of their studies, offering direct insight into the value of the supported research.

2021 – Uday Managala, National Research Council, Pisa

Liquid biopsy for the diagnosis of breast cancer: a project aimed at developing innovative, minimally invasive diagnostic approaches based on the identification of circulating tumor biomarkers, with the goal of improving early detection.

2022 – Fabrizio Fontana, Department of Pharmacological and Biomolecular Sciences, University of Milan

Ovarian cancer: a study focused on the analysis of the molecular and pharmacological mechanisms underlying the disease, with the aim of identifying new therapeutic strategies and potential drug targets.

2023 – Lishan Cui, Catholic University of the Sacred Heart, Rome

Triple-negative breast cancer: research dedicated to one of the most aggressive forms of breast carcinoma, where the identification of new biological mechanisms represents a crucial step toward improving therapeutic options.

2024 – Emanuele Monteleone, University of Turin

Molecular and clinical characterization of extramammary Paget’s disease: a project focused on a rare condition, aimed at deepening the understanding of its molecular and clinical features and promoting increasingly targeted diagnostic and therapeutic approaches.

Also for 2025, Agorà has renewed its commitment by funding a new annual research fellowship dedicated to skin cancers.

An investment that makes a difference

Oncological research is a continuous process that requires sustained investment and a long-term vision. Supporting research means increasing opportunities for early diagnosis, gaining a deeper understanding of the biological mechanisms of disease, and improving the effectiveness of available therapies, with tangible benefits for patient survival and quality of life.

Through this ongoing commitment, Agorà reaffirms its active role in supporting scientific research, firmly believing that studying and understanding cancer today is the key to delivering more effective treatments tomorrow.